Heart rate recovery (HRR) describes the rapid deceleration of heart rate after strenuous exercise and is an indicator of parasympathetic tone. A reduction in parasympathetic tone occurs in patients with congestive heart failure, resulting in prolonged HRR. Acetylcholinesterase inhibitors, such as pyridostigmine, can enhance parasympathetic tone by increasing cholinergic input to the heart. The objective of this study was to develop a rodent model of HRR to test the hypothesis that subacute pyridostigmine administration decreases cholinesterase activity and accelerates HRR in rats. Ten days after implantation of radiotelemetry transmitters, male Sprague Dawley rats were randomized to control (CTL) or treated (PYR; 0.14 mg/mL pyridostigmine in the drinking water, 29 days) groups. Rats were exercised on a treadmill to record HRR, and blood samples were collected on days 0, 7, 14, and 28 of pyridostigmine administration. Total cholinesterase and acetylcholinesterase (AChE) activity in plasma was decreased by 32%-43% and 57%-80%, respectively, in PYR rats on days 7-28, while plasma butyrylcholinesterase activity did not significantly change. AChE activity in red blood cells was markedly reduced by 64%-66%. HRR recorded 1 minute after exercise was higher in the PYR group on days 7, 14 and 28, and on day 7 when HRR was estimated at 3 and 5 minutes. Autonomic tone was evaluated pharmacologically using sequential administration of muscarinic (atropine) and adrenergic (propranolol) blockers. Parasympathetic tone was increased in PYR rats as compared with the CTL group.
recovery (HRR) is the rapid deceleration of heart rate after strenuous exercise and can be easily determined. 8 HRR after submaximal exercise approximates parasympathetic tone in human subjects. [9] [10] [11] As an index of cardiac parasympathetic tone, HRR has clinical utility in predicting cardiovascular fitness, disease prognosis, and mortality in heart failure patients.
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Some of the earliest clinical evaluations of heart rate recovery were performed by Perini and Imai and co-workers. 10, 11 They observed that the early (within 1 minute) recovery of heart rate after exercise is mediated by parasympathetic reactivation. Later, Pierpont and co-workers quantitatively linked HRR to parasympathetic function in healthy volunteers. 17, 18 Shelter and Watanabe validated the use of HRR as a predictor of mortality in human subjects. 13, 19 Despite the importance of HRR to human subjects, there are few studies that support the use of HRR to evaluate parasympathetic tone in rodent models. Barnard (1974) discussed the effect of training rats to near maximal heart rates and subsequent changes in HRR, but did not correlate HRR with changes in cardiac parasympathetic tone.
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Acetylcholinesterase inhibitors, such as pyridostigmine, can increase parasympathetic activity by increasing acetylcholine levels at the vagal cholinergic nerve terminal that innervate cardiac tissue.
Previous studies by Androne and co-workers demonstrated that short term pyridostigmine treatment augmented parasympathetic tone and accelerated HRR in stable CHF patients. 21 Similarly, Serra et al. found that the chronotropic response to exercise in heart failure patients was reduced by the administration of pyridostigmine. 22 There are currently few animal models that have reproduced these findings and could thus serve as a suitable model for further study of the relationship between the autonomic nervous system and heart rate recovery. 23 The objectives of our study were therefore to develop a rodent exercise model of HRR and to use this model to test our hypothesis that subacute administration of pyridostigmine shortens HRR after submaximal exercise in normal rats by increasing cardiac parasympathetic tone.
| RESULTS

| Pyridostigmine intake and in vivo and in vitro inhibition of cholinesterase activity
Pyridostigmine in tap water was stable in the dark at both room temperature and at 4°C, for up to 8 days. During the experimental period, water bottles containing either fresh water (control, CTRL) or freshly-prepared pyridostigmine (PYR) in water were replaced every 3 days. There were no significant differences in body weight gain (CTL 55±4 g; PYR 51±4 g, P=.53) or water consumption (CTL 100±5 mL/kg per day; PYR 106±6 mL/kg per day; P=.47) between the two groups.
Pyridostigmine intake was estimated to be 15±1 mg/kg per day in the PYR group.
Rat plasma contains relatively similar levels of both AChE and BChE, whereas rat red blood cells (RBCs) primar-ily contain only
AChE. 24 Figure 1A shows that the total ChE activity in plasma was decreased by 32%, 43% and 36% (P=.007) in the PYR group relative to controls on days 7, 14 and 28, respectively. Figure 1B shows the effects of PYR on plasma AChE activity, which was reduced by 57%, 80%, and 66% (P<.0001) as compared to control rats on days 7, 14 and 28, respectively. In contrast, there was no significant reduction in plasma BChE activity at any time-point after beginning PYR administration ( Figure 1C ). Similar to reductions in plasma AChE, AChE activity in RBCs was also markedly lower (64%, 66%, and 66%, P<.0001, Figure 1D ) on days 7, 14, and 28 following the initiation of PYR admin- ).
| Heart rate recovery
As shown in Figure 3A , basal HR was similar between groups (P>.28). (P=.02, interaction term, Figure 4A ). However, the HRR3 was significantly higher in the PYR rats on day 7, but not on days 14 or 28 (P=.01, interaction term Figure 4B ). Similarly, on day 7 but not on days 14 or 28, HRR5 was significantly higher in the PRY group as compared with CTL (P=.02, Figure 4C ). Figure 5 shows that parasympathetic tone was increased in the PYR rats as compared to the CTL group, as indicated by a greater bradycardic response (17% decrease in HR) after propranolol administration 
| Autonomic tone and intrinsic heart rate
| DISCUSSION
Heart rate recovery describes the duration of time over which the heart rate decelerates after moderate to heavy exercise and is dependent on the dynamic relationship between the parasympathetic and sympathetic systems. 25 During and after exercise, parasympathetic and sympathetic control of the heart adjusts according to metabolic demands. Savin and colleagues 26 studied cardiac function in normal patients with and without selective autonomic blockers and proposed that sympathetic withdrawal contributes more substantially to this decrease in heart rate soon after exercise, whereas the parasympathetic system predominates later in the recovery phase. However, recent studies have instead proposed that parasympathetic reactivation occurs faster than sympathetic withdrawal, thus playing a major role in the early deceleration of the heart after the termination of exercise. 11, 17, [27] [28] [29] Our study was designed to explore the relative contributions of the sympathetic and parasympathetic systems to heart rate recovery following forced running exercise in rats.
Barnard and co-workers reported relatively few differences in HRR among different ages of rats exercised until exhaustion. 20 To the best of our knowledge, there is no other published literature on HRR in rats for comparison. In order to develop an exercise model of HRR and the cardiac neuroendocrine system in rats, we modified an exercise protocol from a previous study by Copp and co-workers. 30 Using this exercise model, we determined that subacute administration of pyridostigmine in rats does indeed accelerate heart rate recovery ( Figure 4 ). Pyridostigmine can modify parasympathetic control of cardiac function by inhibiting the enzymatic breakdown of acetylcholine
In vitro inhibition of ( ) red blood cell AChE, ( ) plasma AChE and ( ) BChE activity by pyridostigmine (PYR). Tissues were pre-incubated with pyridostigmine for 30 minutes at 26°C prior to adding substrate and measuring residual activity. Enzyme activity was expressed as mean percent of control activity in the absence of inhibitor F I G U R E 3 Basal and maximum heart rate. The (A) basal heart rate before exercise and (B) maximum heart rate at the maximum running speed of 20 m/min was measured on days 0, 7, 14 and 28 during pyridostigmine (PYR) administration. Data are presented as the mean±SEM. †P<.05 compared with day 0. ( ) Control (CTL); ( ) PYR at vagal nerve terminals. This leads to enhanced activation of the muscarinic receptors, affecting cardiac muscle contraction and heart rate.
A single dose of pyridostigmine in CHF patients led to an increase in heart rate recovery recorded at 1 minute after the termination of exercise. 21 In 2007, Dewland et al. showed that in sedentary adults, pyridostigmine decreased resting heart rate and accelerated postexercise heart rate recovery at 1 minute, yet had no significant effect on trained athletes. 31 The study by Dewland and colleagues described post-exercise heart rate recovery as an index of cholinergic signalling in the sinoatrial nodal junction. Similarly, Serra et al. reported that repeated pyridostigmine administration accelerated HRR and other hemodynamic parameters in human CHF patients. 22 Our study also demonstrated that subacute pyridostigmine administration (28 days in the drinking water) accelerated heart rate recovery in rats ( Figure 4 ).
The results from our study thus generally agree with and reflect those previously reported in humans. However, basal heart rate did not differ significantly between treatment groups in our study (Figure 3) , contrasting with an earlier study performed in rats with induced heart failure. 32 This discrepancy may be due to physiological differences between the normal rats used in the current study as compared to those with heart failure. In heart failure rats, a positive chronotropic condition occurs as a consequence of the withdrawal of the parasympathetic and stimulation of the sympathetic systems. 32 As an indirect parasympathomimetic drug, pyridostigmine enhances cardiac vagal tone, thus a greater negative chronotropic effect might be expected in rats with heart failure as compared with a smaller magnitude negative chronotropic effect in normal rats. This smaller magnitude effect, along with day to day variability, may also explain why mean basal HR was not significantly lower in PYR rats as compared to CTL rats, both before exercise and on day 27, just prior to pharmacological estimation of autonomic tone, but was significantly lower on day 29, just before pharmacological manipulations.
Soares et al. reported that 0.14 mg/mL pyridostigmine in the drinking water of rats resulted in an average pyridostigmine intake of 31 mg/ kg per day. 33 These investigators reported that this concentration of pyridostigmine led to approximately 40% inhibition of plasma acetylcholinesterase activity after a 7 day treatment period. 33 Although the average pyridostigmine intake in our study was estimated to be only 15 mg/kg per day, AChE inhibition after 7 days of drug administration was 57% and 64% in rat plasma and RBCs, respectively ( Figure 1 ).
Other studies used the same pyridostigmine dosing conditions in rats as Soares et al. and the resulting dose rate was also higher than that administered in our study. 32, [34] [35] [36] The relatively lower intake of pyridostigmine by our rats may be attributed to higher water intake by the young rats used in the above listed studies, as compared to the older rats used in our study. 37 Moreover, when compared to 28% cholinesterases inhibition by pyridostigmine in HRR studies performed in human subjects and patients with cardiovascular diseases, 38,39 the level of inhibition of acetylcholinesterases were generally higher in our study ( Figure 1 ). The higher dose rate of pyridostigmine in our study may have contributed to the substantial acceleration of HRR ( Figure 4 ).
We noted substantial differences in the magnitude of AChE and BChE inhibition following in vivo PYR exposure (Figure 1 ). We therefore evaluated the relative in vitro sensitivity of AChE and BChE to inhibition by pyridostigmine. In both the RBC and plasma, pyridostigmine was a more potent in vitro inhibitor of AChE as compared to BChE, confirming that pyridostigmine has greater inhibitory effect on AChE than on BChE (Figure 2) . A previous report indicated that in vitro measurements of human and rat AChE may also show differences in sensitivity to pyridostigmine. 40 The slight difference of in vitro sensitivity of AChE in plasma to pyridostigmine vs AChE in RBCs that was noted in our study may be due to differences in PYR metabolism in the plasma vs RBC fractions. Pyridostigmine is a carbamate acetylcholinesterase enzyme inhibitor, and some carbamate anticholinesterases are metabolized by plasma carboxylesterases. Subacute administration of pyridostigmine increased parasympathetic tone but had no apparent effect on sympathetic tone ( Figure 5) in the present study. In contrast, in a previous study of heart failure rats, 32 the authors reported that parasympathetic tone was increased and sympathetic tone was decreased by pyridostigmine administration, with the latter possibly due to the effect of pyridostigmine on cholinergic transmission in the sinoatrial node. However, in both heart failure rats from this previous study and in the normal rats used in our current study, intrinsic heart rate did not differ between the PYR and CTL groups. Pharmacological blockade of the sympathetic and parasympathetic nervous systems by the administration of selective blocking agents are useful for assessing autonomic tone, 29, [43] [44] [45] but the specific manner in which these agents are administered and the subsequent data manipulation can affect the conclusions. Lataro et al. subtracted HR basal from HR atropine to estimate parasympathetic tone, and then subtracted that value from HR propranolol to estimate sympathetic tone. 32 However, after subtracting the basal HR from the HR atropine or HR propranolol , the intrinsic HR still influences HR and confounds the interpretation of relative effects of the autonomic system. We proposed that changes in autonomic tone could be better evaluated by subtracting the intrinsic HR from HR atropine to determine sympathetic tone, then subtracting that value from HR propranolol to estimate parasympathetic tone (Equations 1 and 2 ). This approach may exclude the influence of intrinsic activity while individually isolating the parasympathetic and sympathetic contributions. A similar approach was taken in rats by Ichige et al. where sympathetic tone was calculated as 'HR after atropine minus intrinsic HR' and parasympathetic tone as 'HR after atenolol minus intrinsic HR'. 46 However, the most important finding regarding pharmacological blockade in the current study was confirmation that the anticipated parasympathomimetic effect of pyridostigmine administration correlated with accelerate heart rate recovery in rats. Therefore, modulation of heart rate recovery in rats is potentially a useful model with relevance to common human measures of autonomic tone.
The data support our hypothesis that subacute PYR dosing enhances HRR by increasing cardiac parasympathetic tone in rats.
Post-exercise HRR can be used to assess autonomic tone and thus can serve as an indicator of cardiovascular fitness. The present model of HRR after submaximal exercise should be suitable for future studies in rats with heart failure.
| MATERIAL AND METHODS
| Optimization of experimental methods
Preliminary data were collected from eight, 
| Experimental animals
Sixteen male, 8-9 week-old, Sprague Dawley rats weighing 275-300 g were purchased from Charles River. Only one gender was selected in order to avoid any potential sex-related differences in responses to drug administration. The rats were housed individually and main- After recovering from surgery, each individual rat was trained daily to run on the treadmill, over a 3 day period. After the training period, the rats were exercised as described above and HR data were collected by telemetry. For collection of data, the treadmill was inclined to a 10% grade and the speed of the treadmill was increased by 5 m/ min every 3 minutes until reaching a speed of 20 m/min, which was maintained for 6 minutes. The treadmill was then stopped and the rats were allowed to rest on the treadmill for 5 minutes.
| Surgical implantation of radiotelemetry device
| Pyridostigmine treatment
After recovery from the surgery, rats were randomly divided into pyridostigmine treated (PYR) and control (CTL) groups (n=8 per group).
The PYR group received 0.14 mg/mL [33] [34] [35] of pyridostigmine dissolved in drinking water, whereas the CTL rats received only water, both for 29 days. Stability of pyridostigmine in water was confirmed by serial quantification using mass spectrometry. Pyridostigmine (0.14 mg/mL) in water was stable in both ambient and cold (4°C) temperatures for up to 8 days.
| Assessment of heart rate recovery
Heart rate recovery (beats/min) was determined by subtracting the heart rate at 1, 3 and 5 minutes after exercise from the maximum heart rate achieved at a speed of 20 m/min. The HRR at 1, 3, and 5 minutes after termination of exercise were termed HRR1, HRR3 and HRR5.
Heart rate recovery data were collected on days 0 (pre-treatment), 7, 14 and 28 after initiating PYR administration.
| Acetylcholinesterase and butyrylcholinesterase activity
Blood samples were collected from the retro-orbital plexus, under isoflurane general inhalation anaesthesia, on days 0, 7, 14 and 28 for determining blood cholinesterase (ChE) activities. An aliquot of whole blood was collected, and plasma and RBCs were separated by centrifugation (5000× g, 2 minutes). The RBCs were washed by resuspension in phosphate buffered saline solution, centrifuged as before, and the supernatant was discarded. The washing step was repeated three times. Plasma and washed RBCs were then stored at −80°C until analysis. Acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and total ChE activity were measured in the plasma, whereas only AChE activity was measured in RBCs, using a radiometric method with [ 
| Pharmacological determination of autonomic tone
Autonomic tone was assessed in freely moving, conscious rats. On day 27, basal heart rate (HR basal ) was recorded for 10 minutes. Atropine sulphate (Henry Schein, Dublin, OH, USA) was injected intraperitoneally, at a dose of 2 mg/kg [48] [49] [50] to block parasympathetic input to the heart.
The HR recorded 15 minutes after atropine injection was defined as HR atropine , i.e., HR where cholinergic inputs have been blocked. 
| Statistical analysis
All data are presented as the mean±SEM. Comparison of the basal HR and maximum HR were performed using a two way repeated measures ANOVA followed by Dunnett's test for multiple comparisons. Similarly, HRR and ChE enzyme activity were analyzed using a repeated measures two way ANOVA followed by Sidak's (to compare between treatment groups) and Dunnett's (to compare day 7, 14 and 28 with day 0) test for multiple comparisons. For measurements that were obtained only once (i.e., sympathetic tone, parasympathetic tone, intrinsic HR, weight gain, and water intake), a Student's t test was selected. The level of significance was set at α<0.05. In vitro inhibition data were fitted to a nonlinear curve to calculate the IC 50 by using nonlinear curve fitting of inhibitor dose response function in GraphPad prism 6 (GraphPad Software, La Jolla, CA, USA).
